Mutations in Prostate Cancer (Part 2)

Following this presentation, attendees will be able to:

• Appreciate the unmet needs in the management  mCRPC
• Discuss PARP inhibition in pathways beyond BRCA
• Discuss results from the PROfound trial in patients with HRR gene-mutated mCRPC who have progressed following prior treatment with abiaterone or enzalutamide.

Date: Wednesday October 13, 2021
Time: 12:00 PM ET
Virtual Platform: GoToWebinar
Presenter: Stella Redfern, Ph.D. Senior Medical Director GU/GI Biomarker and Diagnostics
Target Audience: Primary Care, Urologists, Oncologists, Nurses, Pharmacists and other Healthcare professional who care for patients with mCRPC

Fee: $0
CME/CE: 0 hrs

This web series is sponsored by: